meta|Evidence - COVID-19
click on circles to display study description...
DPP-4 inhibitor (n=32) vs. standard of care (n=32)
randomized controlled trial some concerns about risk of bias
linagliptine
5 mg/dfrom randomization to hospital discharge
standard of care
diabetes treatment included holding oral drugs and initiating insulin therapy according to a basal bolus protocol. The goal of therapy was to keep blood glucose levels in the range of 140–180 mg/dl.
COVID-19 severe or critically
open-label
3 centers, Israel
Clinical change is defined as 2 points reduction in the 9-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement
The trial was prematurely terminated due to the control of the COVID-19 outbreak in Israel.
powered by vis.js Network